| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$9.9M | ROE | −3325.71% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $2.0M | Trading Days | 4628 |
| 52W High | 0.15 |
| 52W Low | 0.02 |
| % Off High | −73.42% |
| YTD | −33.55% | 1Y | −73.42% |
| 3Y | −99.82% | 5Y | −99.97% |
| 10Y | −99.99% | Since incept. (ann.) | −36.71% |
| Ann. Volatility (1Y) | 213.11% | Ann. Volatility (3Y) | 189.66% |
| Sharpe (1Y) | 0.41 | Sharpe (3Y) | −0.22 |
| Max Drawdown (1Y) | −87.67% | Max Drawdown (3Y) | −99.92% |
| Beta (3Y, vs SPY) | −1.14 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ARTL | ARTELO BIOSCIENCES, INC. | $2.1M | — |
| AZTR | Azitra, Inc. | $2.1M | — |
| DCOY | Decoy Therapeutics Inc. | $2.1M | — |
| NXTS | Nexentis Technologies Inc. | $2.2M | — |
| MTNB | Matinas BioPharma Holdings, Inc. | $1.9M | — |
| VCNX | VACCINEX, INC. | $2.2M | — |
| OGEN | ORAGENICS INC | $2.2M | — |
| GRI | GRI Bio, Inc. | $2.5M | — |
| PKTX | ProtoKinetix, Inc. | $2.6M | — |
| HEPA | Hepion Pharmaceuticals, Inc. | $1.3M | — |
| ACUT | Accustem Sciences Inc. | $3.5M |
| ENSC | Ensysce Biosciences, Inc. | $3.7M | — |
